Product

Trastuzumab, Capecitabine and Cisplatin

1 clinical trial

1 indication

Indication

Gastric or Gastroesophageal Junction Adenocarcinoma

Clinical trial

A Phase II Clinical Study of Trastuzumab in Combination With Capecitabine and Cisplatin (XP) in Patients With Tissue HER2-negative But Serum HER2-positive Advanced Gastric Cancer: XP+Samfenet

Status: Recruiting, Estimated PCD: 2024-12-31